

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 12

```
=> s l3 ful
FULL SEARCH INITIATED 10:39:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 121437 TO ITERATE
```

L6 118 SEA SSS FUL L3

FILE 'CAPLUS' ENTERED AT 10:39:22 ON 15 NOV 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 15 Nov 2005 VOL 143 ISS 21  
FILE LAST UPDATED: 14 Nov 2005 (20051114/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 16

L7 5 L6

=> s 17 not 15

L8 4 L7 NOT L5

=> d bib hitstr 4

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1974:471055 CAPLUS

DN 81:71055

TI Color photographic sensitive materials

IN Yanagi, Hajime; Ito, Susumu

PA Oriental Photo Industrial Co., Ltd.

SO Jpn. Tokkyo Koho, 8 pp.

CODEN: JAXXAD

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 48040423	B4	19731130	JP 1969-3943	19690120
PRAI	JP 1969-3943		19690120		
IT	53248-73-0				

RL: TEM (Technical or engineered material use); USES (Uses)  
(photog. cyan coupler)

RN 53248-73-0 CAPLUS

CN 1H-Isoindole-5-carboxylic acid, 2-[3-[[[2-[[[4-bromo-1-hydroxy-2-naphthalenyl)carbonyl]amino]ethyl]amino]carbonyl]-4-(octadecyloxy)phenyl]-2,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)



=> d bib hit 1-3

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:767774 CAPLUS

DN 139:286334

TI Amino acid derivatives and their use as integrin  $\alpha 4$  (adhesion molecule) inhibitors and in therapeutic agents for inflammatory diseases

IN Ishigaki, Takeshi; Taniguchi, Koji; Ito, Takayoshi; Ono, Hiroshi; Kaino, Mie; Meguro, Hiroyuki

PA Toray Industries, Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 247 pp.

CODEN: JKXXAF

DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2003277340	A2	20031002	JP 2002-81956	20020322
PRAI	JP 2002-81956		20020322		
OS	MARPAT 139:286334				
IT	607395-68-6P	607395-69-7P	607395-70-0P	607395-71-1P	607395-72-2P
	607395-73-3P	607395-74-4P	607395-75-5P	607395-76-6P	607395-77-7P
	607395-78-8P	607395-79-9P	607395-80-2P	607395-81-3P	607395-82-4P
	607395-83-5P	607395-84-6P	607395-85-7P	607395-86-8P	607395-87-9P
	607395-88-0P	607395-89-1P	607395-92-6P	607395-93-7P	607395-94-8P
	607395-95-9P	607395-96-0P	607395-97-1P	607395-98-2P	607395-99-3P
	607396-00-9P	607396-01-0P	607396-02-1P	607396-03-2P	607396-04-3P
	607396-05-4P	607396-06-5P	607396-07-6P	607396-08-7P	607396-09-8P
	607396-10-1P	607396-11-2P	607396-12-3P	607396-13-4P	607396-14-5P
	607396-15-6P	607396-16-7P	607396-17-8P	607396-18-9P	607396-19-0P
	607396-20-3P	607396-21-4P	607396-22-5P	607396-23-6P	607396-24-7P
	607396-25-8P	607396-26-9P	607396-27-0P	607396-28-1P	607396-29-2P
	607396-30-5P	607396-31-6P	607396-32-7P	607396-33-8P	607396-34-9P
	607396-35-0P	607396-36-1P	607396-37-2P	607396-38-3P	607396-39-4P
	607396-40-7P	607396-41-8P	607396-42-9P	607396-43-0P	607396-44-1P
	607396-45-2P	607396-46-3P	607396-47-4P	607396-48-5P	607396-49-6P
	607396-50-9P	607396-51-0P	607396-52-1P	607396-53-2P	607396-54-3P
	607396-55-4P	607396-56-5P	607396-57-6P	607396-58-7P	607396-59-8P
	607396-60-1P	607396-61-2P	607396-62-3P	607396-63-4P	607396-64-5P
	607396-65-6P	607396-66-7P	607396-67-8P	607396-68-9P	607396-69-0P
	607396-70-3P	607396-71-4P	607396-72-5P	607396-73-6P	607396-74-7P
	607396-75-8P	607396-76-9P	607396-77-0P	607396-78-1P	607396-79-2P
	607396-80-5P	607396-81-6P	607396-82-7P	607396-83-8P	607396-84-9P
	607396-85-0P	607396-86-1P	607396-87-2P	607396-88-3P	607396-89-4P
	607396-90-7P	607396-91-8P	607396-92-9P	607396-93-0P	607396-94-1P
	607396-95-2P	607396-96-3P	607396-98-5P	607396-99-6P	607397-00-2P
	607397-01-3P	607397-02-4P	607397-03-5P	607397-04-6P	607397-05-7P
	607397-06-8P	607397-07-9P	607397-08-0P	607397-09-1P	607397-10-4P
	607397-11-5P	607397-12-6P	607397-13-7P	607397-14-8P	607397-15-9P
	607397-16-0P	607397-17-1P	607397-18-2P	607397-19-3P	607397-20-6P
	607397-21-7P	607397-22-8P	607397-23-9P	607397-24-0P	607397-25-1P
	607397-26-2P	607397-27-3P	607397-28-4P	607397-29-5P	607397-30-8P
	607397-31-9P	607397-32-0P	607397-33-1P	607397-34-2P	607397-35-3P
	607397-36-4P	607397-37-5P	607397-38-6P	607397-39-7P	607397-40-0P
	607397-41-1P	607397-42-2P	607397-43-3P	607397-44-4P	607397-45-5P
	607397-46-6P	607397-47-7P	607397-48-8P	607397-49-9P	607397-50-2P
	607397-51-3P	607397-52-4P	607397-53-5P	607397-54-6P	607397-55-7P
	607397-56-8P	607397-57-9P	607397-58-0P	607397-59-1P	607397-60-4P
	607397-61-5P	607397-62-6P	607397-63-7P	607397-64-8P	607397-65-9P
	607397-66-0P	607397-67-1P	607397-68-2P	607397-69-3P	607397-70-6P
	607397-71-7P	607397-72-8P	607397-73-9P	607397-74-0P	607397-75-1P
	607397-76-2P	607397-77-3P	607397-78-4P	607397-79-5P	607397-80-8P
	607397-81-9P	607397-82-0P	607397-83-1P	607397-84-2P	607397-85-3P
	607397-86-4P	607397-87-5P	607397-88-6P	607397-89-7P	607397-90-0P
	607397-91-1P	607397-92-2P	<b>607397-93-3P</b>	607397-94-4P	
	607397-95-5P	607397-96-6P	607397-97-7P	607397-98-8P	607397-99-9P
	607398-00-5P	607398-01-6P	607398-02-7P	<b>607398-03-8P</b>	
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses) (preparation of amino acid derivs. as integrin $\alpha$ 4 inhibitors for treatment of inflammatory diseases)					
IT	607398-04-9P	607398-05-0P	607398-06-1P	607398-07-2P	607398-08-3P
	607398-09-4P	607398-10-7P	607398-11-8P	<b>607398-12-9P</b>	

607398-13-0P	607398-14-1P	607398-15-2P	607398-16-3P	607398-17-4P
607398-18-5P	607398-19-6P	607398-20-9P	<b>607398-21-0P</b>	
607398-22-1P	607398-23-2P	607398-24-3P	607398-25-4P	607398-26-5P
607398-27-6P	607398-28-7P	607398-29-8P	<b>607398-30-1P</b>	
607398-31-2P	607398-32-3P	607398-33-4P	607398-34-5P	607398-35-6P
607398-36-7P	607398-37-8P	607398-38-9P	<b>607398-39-0P</b>	
607398-40-3P	607398-41-4P	607398-42-5P	607398-43-6P	607398-44-7P
607398-45-8P	607398-46-9P	607398-47-0P	607398-48-1P	
<b>607398-49-2P</b>	607398-50-5P	607398-51-6P	607398-52-7P	
607398-53-8P	607398-54-9P	607398-55-0P	607398-56-1P	607398-57-2P
607398-58-3P	607398-59-4P	607398-60-7P	607398-61-8P	607398-62-9P
607398-63-0P	607398-64-1P	607398-65-2P	607398-66-3P	607398-67-4P
607398-68-5P	607398-69-6P	607398-70-9P	607398-71-0P	607398-72-1P
607398-73-2P	607398-74-3P	607398-75-4P	607398-76-5P	607398-77-6P
607398-78-7P	607398-79-8P	607398-80-1P	607398-81-2P	607398-82-3P
607398-83-4P	607398-84-5P	607398-85-6P	607398-86-7P	607398-87-8P
607398-88-9P	607398-89-0P	607398-90-3P	607398-91-4P	607398-92-5P
607398-93-6P	607398-94-7P	607398-95-8P	607398-96-9P	607398-97-0P
607398-98-1P	607398-99-2P	607399-00-8P	607399-01-9P	607399-02-0P
607399-03-1P	607399-04-2P	607399-05-3P	607399-06-4P	607399-07-5P
607399-08-6P	607399-09-7P	607399-10-0P	607399-11-1P	607399-12-2P
607399-13-3P	607399-14-4P	607399-15-5P	607399-16-6P	607399-17-7P
607399-18-8P	607399-19-9P	607399-20-2P	607399-21-3P	607399-22-4P
607399-23-5P	607399-25-7P	607399-26-8P	607399-27-9P	607399-28-0P
607399-29-1P	607399-30-4P	607399-31-5P	607399-32-6P	607399-33-7P
607399-34-8P	607399-35-9P	607399-36-0P	607399-37-1P	607399-38-2P
607399-39-3P	607399-40-6P	607399-41-7P	607399-42-8P	607399-43-9P
607399-44-0P	607399-46-2P	607399-48-4P	607399-49-5P	607399-51-9P
607399-53-1P	607399-55-3P	607399-57-5P	607399-59-7P	607399-60-0P
607399-62-2P	607399-63-3P	607399-65-5P	607399-67-7P	607399-69-9P
607399-70-2P	607399-72-4P	607399-74-6P	607399-76-8P	607399-79-1P
607399-80-4P	607399-83-7P	607399-84-8P	607399-85-9P	607399-87-1P
607399-89-3P	607399-90-6P	607399-92-8P	607399-93-9P	607399-95-1P
607399-96-2P	607399-98-4P	607400-00-0P	607400-02-2P	607400-04-4P
607400-06-6P	607400-07-7P	607400-08-8P	607400-09-9P	607400-11-3P
607400-12-4P	607400-13-5P	607400-14-6P	607400-15-7P	607400-16-8P
607400-17-9P	607400-18-0P	607400-19-1P	607400-20-4P	607400-21-5P
607400-22-6P	607400-23-7P	607400-24-8P	607400-25-9P	607400-26-0P
607400-27-1P	607400-28-2P	607400-29-3P	607400-30-6P	607400-31-7P
607400-32-8P	607400-34-0P	607400-35-1P	607400-36-2P	607400-37-3P
607400-38-4P	607400-39-5P	607400-41-9P	607400-42-0P	607400-43-1P
607400-45-3P	607400-47-5P	607400-48-6P	607400-49-7P	607400-51-1P
607400-52-2P	607400-53-3P	607400-54-4P	607400-55-5P	607400-56-6P
607400-57-7P	607400-58-8P	607400-59-9P	607400-60-2P	607400-61-3P
607400-62-4P	607400-63-5P	607400-64-6P	607400-66-8P	607400-67-9P
607400-68-0P	607400-69-1P	607400-70-4P	607400-71-5P	

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(preparation of amino acid derivs. as integrin  $\alpha 4$  inhibitors for treatment of inflammatory diseases)

IT	607400-73-7P	607400-74-8P	607400-75-9P	607400-76-0P	607400-77-1P
	607400-78-2P	607400-79-3P	607400-80-6P	607400-81-7P	607400-82-8P
	607400-83-9P	607400-84-0P	607400-85-1P	607400-86-2P	607400-87-3P
	607400-88-4P	607400-89-5P	607400-90-8P	607400-91-9P	607400-92-0P
	607400-93-1P	607400-94-2P	607400-95-3P	607400-96-4P	607400-97-5P
	607400-98-6P	607400-99-7P	607401-00-3P	607401-01-4P	607401-02-5P
	607401-04-7P	607401-05-8P	607401-07-0P	607401-08-1P	607401-09-2P
	607401-10-5P	607401-11-6P	607401-12-7P	607401-14-9P	607401-15-0P
	607401-17-2P	607401-19-4P	607401-21-8P	607401-23-0P	607401-24-1P
	607401-25-2P	607401-27-4P	607401-29-6P	607401-30-9P	607401-31-0P
	607401-32-1P	607401-33-2P	607401-34-3P	607401-35-4P	607401-36-5P

607401-37-6P 607401-39-8P 607401-40-1P 607401-42-3P 607401-44-5P  
607401-46-7P 607401-49-0P 607401-51-4P 607401-53-6P 607401-55-8P  
607401-56-9P **607401-58-1P** 607401-60-5P 607401-62-7P  
607401-64-9P 607401-66-1P 607401-68-3P 607401-70-7P 607401-72-9P  
607401-74-1P 607401-76-3P 607401-78-5P **607401-80-9P**  
607401-82-1P 607401-84-3P 607401-85-4P 607401-87-6P 607401-88-7P  
607401-89-8P 607401-90-1P 607401-91-2P 607401-92-3P 607401-93-4P  
**607401-94-5P** 607401-95-6P 607401-96-7P 607401-97-8P  
607401-99-0P 607402-00-6P 607402-02-8P 607402-04-0P 607402-05-1P  
607402-07-3P 607402-09-5P 607402-11-9P 607402-13-1P 607402-15-3P  
607402-17-5P 607402-19-7P 607402-21-1P 607402-23-3P 607402-25-5P  
607402-27-7P 607402-29-9P 607402-30-2P 607402-32-4P 607402-33-5P  
607402-34-6P 607402-35-7P 607402-36-8P 607402-37-9P 607402-38-0P  
607402-39-1P 607402-40-4P 607402-41-5P 607402-42-6P 607402-43-7P  
607402-44-8P 607402-45-9P 607402-46-0P 607402-47-1P 607402-48-2P  
607402-49-3P 607402-50-6P 607402-51-7P 607402-52-8P 607402-53-9P  
607402-54-0P 607402-55-1P 607402-56-2P 607402-57-3P 607402-59-5P  
607402-60-8P 607402-61-9P 607402-62-0P 607402-63-1P 607402-64-2P  
607402-65-3P 607402-66-4P 607402-67-5P 607402-68-6P 607685-19-8P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU  
(Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study);  
PREP (Preparation); USES (Uses)

(preparation of amino acid derivs. as integrin  $\alpha 4$  inhibitors for  
treatment of inflammatory diseases)

IT 607395-44-8P 607395-46-0P **607395-48-2P** **607395-50-6P**

**607395-52-8P** **607395-54-0P** **607395-56-2P**

607395-58-4P 607395-60-8P 607395-61-9P 607395-63-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of amino acid derivs. as integrin  $\alpha 4$  inhibitors for  
treatment of inflammatory diseases)

IT 264274-57-9P 607395-45-9P 607395-47-1P **607395-49-3P**

**607395-51-7P** **607395-53-9P** **607395-55-1P**

**607395-57-3P** 607395-59-5P 607395-62-0P 607395-64-2P

607395-65-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of amino acid derivs. as integrin  $\alpha 4$  inhibitors for  
treatment of inflammatory diseases)

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:240774 CAPLUS

DN 136:279698

TI Preparation of 2-amino-3-[(triazaspiroalkanecarbonyl)amino]propanoic acid  
derivatives as adhesion molecule inhibitors

IN Takahashi, Toshiya; Ishigaki, Takeshi; Funahashi, Miyuki; Taniguchi, Koji;  
Kaneko, Masayuki; Kainoh, Mie; Meguro, Hiroyuki

PA Toray Industries, Inc., Japan

SO PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002024697	A1	20020328	WO 2001-JP8290	20010925
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,  
 US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2001088114 A5 20020402 AU 2001-88114 20010925  
 CA 2423007 AA 20030324 CA 2001-2423007 20010925  
 EP 1329451 A1 20030723 EP 2001-967819 20010925  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 US 2004087574 A1 20040506 US 2003-381367 20030325  
 US 6919349 B2 20050719  
 PRAI JP 2000-289658 A 20000925  
 WO 2001-JP8290 W 20010925

OS MARPAT 136:279698

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 406478-34-0P 406478-35-1P 406478-36-2P 406478-37-3P 406478-38-4P  
 406478-39-5P 406478-40-8P 406478-41-9P 406478-42-0P 406478-43-1P  
 406478-44-2P 406478-45-3P 406478-46-4P 406478-48-6P 406478-49-7P  
 406478-50-0P 406478-51-1P 406478-52-2P 406478-53-3P 406478-54-4P  
 406478-55-5P 406478-56-6P 406478-57-7P 406478-58-8P 406478-59-9P  
 406478-60-2P 406478-61-3P 406478-62-4P 406478-63-5P  
 406478-64-6P 406478-65-7P 406478-66-8P  
 406478-67-9P 406478-68-0P 406478-69-1P 406478-70-4P  
 406478-71-5P 406478-72-6P 406478-73-7P 406478-74-8P 406478-75-9P  
 406478-76-0P 406478-77-1P 406478-78-2P 406478-79-3P 406478-80-6P  
 406478-81-7P 406478-82-8P 406478-83-9P 406478-84-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of amino[(triazaspiroalkanecarbonyl)amino]propanoic acid  
 derivs. as adhesion mol. inhibitors for treatment of inflammatory  
 diseases)

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1981:84573 CAPLUS

DN 94:84573

TI Poly(amido imides) containing a bicyclo[2.2.2]octene ring in their main  
 chains

AU Kobayashi, Kesayoshi; Suzuki, Akira; Shimizu, Masamoto; Shirai, Hirofusa;  
 Hojo, Nobumasa

CS Fac. Text. Sci. Technol., Shinshu Univ., Ueda, 386, Japan

SO Nippon Kagaku Kaishi (1980), (12), 1929-32

CODEN: NKAKB8; ISSN: 0369-4577

DT Journal

LA Japanese

IT 76585-98-3P 76585-99-4P 76586-00-0P 76586-01-1P  
 76586-02-2P 76586-03-3P 76586-04-4P 76586-05-5P 76586-06-6P  
 76586-07-7P 76586-08-8P 76586-09-9P 76586-10-2P 76586-11-3P  
 76586-12-4P 76601-06-4P 76601-07-5P 76601-08-6P 76601-09-7P  
 76601-10-0P 76601-11-1P 76601-12-2P 76601-13-3P 76601-14-4P  
 76601-15-5P 76601-16-6P 76601-17-7P 76601-18-8P 76601-19-9P  
 76613-90-6P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and thermal properties of)

=> d hitstr 3

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN


IT 76585-98-3P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(preparation and thermal properties of)

RN 76585-98-3 CAPLUS

CN Poly[(3a,4,4a,5,7,7a,8,8a-octahydro-1,3,5,7-tetraoxo-4,8-ethenobenzo[1,2-c:4,5-c']dipyrrole-2,6(1H,3H)-diyl)-1,4-phenylenecarbonylimino-1,2-ethanediyiminocarbonyl-1,4-phenylene] (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

[  
n

=> d hitstr 2

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

IT 406478-62-4P 406478-63-5P 406478-64-6P

406478-65-7P 406478-66-8P 406478-67-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of amino[(triazaspiroalkanecarbonyl)amino]propanoic acid  
derivs. as adhesion mol. inhibitors for treatment of inflammatory  
diseases)

RN 406478-62-4 CAPLUS

CN L-Alanine, N-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-  
piperidinyl]carbonyl]-3-[[[4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-  
yl)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 406478-63-5 CAPLUS

CN L-Alanine, N-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]-3-[[[4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 406478-64-6 CAPLUS

CN L-Alanine, N-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]-3-[[[4-oxo-1-phenyl-3-(phenylmethyl)-1,3,8-triazaspiro[4.5]dec-8-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 406478-65-7 CAPLUS

CN L-Alanine, N-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]-3-[[[4-oxo-1-phenyl-3-(phenylmethyl)-1,3,8-triazaspiro[4.5]dec-8-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 406478-66-8 CAPLUS

CN L-Alanine, N-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidiny]carbonyl]-3-[[[3-(2-methylpropyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 406478-67-9 CAPLUS

CN L-Alanine, N-[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidiny]carbonyl]-3-[[[3-(2-methylpropyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d hitstr 1

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

IT 607397-93-3P 607398-03-8P 607398-12-9P  
607398-21-0P 607398-30-1P 607398-39-0P  
607398-49-2P 607401-58-1P 607401-80-9P  
607401-94-5P


RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(preparation of amino acid derivs. as integrin  $\alpha 4$  inhibitors for treatment of inflammatory diseases)

RN 607397-93-3 CAPLUS

CN L-Alanine, 3-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-N-(1-naphthalenylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607398-03-8 CAPLUS

CN L-Alanine, N-(3,5-dichlorobenzoyl)-3-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607398-12-9 CAPLUS


CN L-Alanine, N-[3,5-bis(trifluoromethyl)benzoyl]-3-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607398-21-0 CAPLUS  
 CN L-Alanine, N-(2,6-difluorobenzoyl)-3-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607398-30-1 CAPLUS  
 CN L-Alanine, 3-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-N-(2,4,6-trichlorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 607398-39-0 CAPLUS  
 CN L-Alanine, 3-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-N-(2,3,5,6-tetrafluorobenzoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607398-49-2 CAPLUS

CN L-Alanine, N-benzoyl-3-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607401-58-1 CAPLUS

CN L-Alanine, 3-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-N-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607401-80-9 CAPLUS


CN L-Alanine, 3-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-N-(2,6-dimethoxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607401-94-5 CAPLUS  
CN L-Alanine, 3-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-N-[4-(trifluoromethoxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 607395-48-2P 607395-50-6P 607395-52-8P  
607395-54-0P 607395-56-2P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of amino acid derivs. as integrin  $\alpha$ 4 inhibitors for treatment of inflammatory diseases)  
RN 607395-48-2 CAPLUS  
CN L-Alanine, N-(2,6-dichlorobenzoyl)-3-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607395-50-6 CAPLUS

CN L-Alanine, N-(2,6-dichlorobenzoyl)-3-[[[4-(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607395-52-8 CAPLUS

CN L-Alanine, N-(2,6-dichlorobenzoyl)-3-[[[4-[2,3-dihydro-2-oxo-3-(phenylmethyl)-1H-benzimidazol-1-yl]-1-piperidinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607395-54-0 CAPLUS

CN L-Alanine, N-(2,6-dichlorobenzoyl)-3-[[[4-(2,3-dihydro-2-oxo-3-propyl-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 607395-56-2 CAPLUS

CN L-Alanine, N-(2,6-dichlorobenzoyl)-3-[[[4-[2,3-dihydro-3-(2-methylpropyl)-2-oxo-1H-benzimidazol-1-yl]-1-piperidinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 607395-49-3P 607395-51-7P 607395-53-9P  
607395-55-1P 607395-57-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acid derivs. as integrin  $\alpha 4$  inhibitors for treatment of inflammatory diseases)

RN 607395-49-3 CAPLUS

CN L-Alanine, N-(2,6-dichlorobenzoyl)-3-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607395-51-7 CAPLUS

CN L-Alanine, N-(2,6-dichlorobenzoyl)-3-[[[4-(2,3-dihydro-3-methyl-2-oxo-1H-benzimidazol-1-yl)-1-piperidiny]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607395-53-9 CAPLUS

CN L-Alanine, N-(2,6-dichlorobenzoyl)-3-[[[4-[2,3-dihydro-2-oxo-3-(phenylmethyl)-1H-benzimidazol-1-yl]-1-piperidiny]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607395-55-1 CAPLUS

CN L-Alanine, N-(2,6-dichlorobenzoyl)-3-[[[4-(2,3-dihydro-2-oxo-3-propyl-1H-benzimidazol-1-yl)-1-piperidiny]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607395-57-3 CAPLUS


CN L-Alanine, N-(2,6-dichlorobenzoyl)-3-[[[4-[2,3-dihydro-3-(2-methylpropyl)-2-oxo-1H-benzimidazol-1-yl]-1-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>

<-----User Break----->



REP G1=(1-2) CH  
 ENTER (DIS), GRA, NOD, BON OR ?:end  
 L3 STRUCTURE CREATED

=> s 13

SAMPLE SEARCH INITIATED 10:36:22 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 6108 TO ITERATE

32.7% PROCESSED 2000 ITERATIONS  
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
 SEARCH TIME: 00.00.01


1 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 117475 TO 126845  
 PROJECTED ANSWERS: 1 TO 165

L4 1 SEA SSS SAM L3

=> d

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 678177-12-3 REGISTRY  
 ED Entered STN: 30 Apr 2004  
 CN 2-Thiophenecarboxamide, 5-chloro-N-[1-[[2-(4-methyl-1-piperazinyl)ethoxy]methyl]-2-[[4-(2-oxo-1(2H)-pyridinyl)benzoyl]amino]ethyl]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C27 H32 Cl N5 O4 S  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.56	3.77

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:36:34 ON 15 NOV 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Nov 2005 VOL 143 ISS 21  
FILE LAST UPDATED: 14 Nov 2005 (20051114/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 14  
L5


1 L4

=> d bib abs hitstr

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:308415 CAPLUS  
DN 140:321240  
TI Preparation of lactam-containing diaminoalkanes,  $\beta$ -amino acids,  $\alpha$ -amino acids and derivatives thereof as factor Xa inhibitors  
IN Qiao, Jennifer X.; Han, Wei  
PA Bristol-Myers Squibb Company, USA  
SO PCT Int. Appl., 172 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2004031145	A2	20040415	WO 2003-US31079	20031001
	WO 2004031145	A3	20040701		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,				

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 US 2004077635 A1 20040422 US 2003-677063 20031001  
 EP 1558606 A2 20050803 EP 2003-773077 20031001  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 PRAI US 2002-415366P P 20021002  
 US 2002-417208P P 20021009  
 WO 2003-US31079 W 20031001  
 OS MARPAT 140:321240  
 GI



AB The title compds. PMM1 [I; one of P and M1 = G and the other -AB; G = II, III (wherein ring D, including the two carbon atoms of ring E to which it is attached, is (un)substituted 5-6 membered ring consisting of carbon atoms and 0-3 heteroatoms selected from N, O, S(O)0-2; ring D may contain 0-3 ring double bonds; ring E = (un)substituted Ph, pyridyl, pyrimidinyl, etc.; alternatively, ring D is absent); M = (un)substituted 3-8 membered linear chain consisting of carbon atoms, carbonyl groups, thiocarbonyl, heteroatoms, and there are 0-2 double bonds and 0-1 triple bond; A = (un)substituted carbocycle, 5-12 membered heterocycle; B = IV (wherein Q1 = CO, SO2; ring Q = (un)substituted 4-8 membered monocyclic or bicyclic ring optionally containing optionally heteroatoms, and optionally fused, etc.; X = absent, CO, SO, SO2, etc.)], useful as inhibitors of trypsin-like serine proteases, specifically factor Xa for treating thromboembolic disorder, were prepared E.g., a 3-step synthesis of V, starting from 1-(4-aminophenyl)-1H-pyridin-2-one and Boc-DL-PHG-OH, was given. The number of compds. I were found to exhibit Ki's of  $\leq 10 \mu\text{M}$  against human factor Xa. The pharmaceutical composition comprising the compound I is claimed.

IT 678177-12-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of lactam-containing diaminoalkanes,  $\beta$ -amino acids,  $\alpha$ -amino acids and derivs. thereof as factor Xa inhibitors for treating thromboembolic disorder)

RN 678177-12-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-chloro-N-[1-[[2-(4-methyl-1-piperazinyl)ethoxy)methyl]-2-[[4-(2-oxo-1(2H)-pyridinyl)benzoyl]amino]ethyl]- (9CI) (CA INDEX NAME)

